- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00244283
A Comparison of Two Anaesthetic Methods of Protecting Heart Tissue During Cardiac Surgery
A Comparison of Myocardial Protection Using Preconditioning With Sevoflurane Against High Thoracic Epidural Analgesia for CABG Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Coronary artery bypass grafting (CABG) is a common procedure performed to improve blood flow to the heart in patients with severe ischaemic heart disease. Commonly, the heart has to be stopped to allow this procedure to be performed and this is often achieved with cooling the heart and perfusing it with a solution that stops the activity of the heart muscle. These techniques stop the heart from beating which allows the surgery to be performed and also reduce the oxygen requirements of the heart. This in turn reduces the damage the heart suffers from the reduced blood flow to it which occurs while the arteries are being operated on. Unfortunately, however, these techniques do not completely eliminate the risk of heart muscle damage and so new methods of further reducing damage to the heart are continually being investigated. Two methods relating to the anaesthetic techniques used have recently been identified as potentially of benefit in this regard - the use of volatile anaesthetic agents and the use of high thoracic epidural analgesia.
Volatile anaesthetic agents have been extensively investigated in the past few years with regard to their apparent ability to mimic ischaemic preconditioning. Ischaemic preconditioning refers to the phenomenon that if heart tissue is exposed to frequent, short episodes of reduced blood or oxygen supply, followed by a longer spell, the heart is likely to suffer a smaller area of damage than if it had never been exposed to the brief ischaemic spells. This can be related clinically to the observation that patients with angina, who subsequently suffer a heart attack, have a better prognosis than those patients who suffer a heart attack without ever experiencing angina prior to the event. There have been numerous studies demonstrating that the volatile anaesthetic agents (isoflurane, sevoflurane, desflurane) appear to mimic this phenomenon, both in animal and human models. Numerous studies have demonstrated favourable postoperative blood concentrations of cardiac troponin I (a sensitive marker of heart damage), CK-MB (another marker of heart damage), atrial and brain natriueretic peptides (markers of heart function) compared to those who did not receive preconditioning. It has therefore been suggested that this may improve outcome following cardiac surgery.
High thoracic epidural analgesia (HTEA) has also been shown to be beneficial following cardiac surgery. This involves placing a small catheter near the nerves as they leave the spinal cord. Local anaesthetic ccan be administered down this catheter to numb the areas of the body supplied by these nerves. This provides very good pain relief and is widely used in our hospital for this operation. It has been shown to be associated with a shorter time of required artificial ventilation compared to standard pain relief with drugs such as morphine. It has also been suggested that it may influence outcome with improved heart function following the operation compared to those without HTEA. It appears to do this by improving the blood flow to the heart. It has also been associated with a lower postoperative concentration of cardiac troponin , CK-MB, atrial and brain natriuretic peptides. There has not been any direct comparison of the two techniques, however, to assess if one is superior to the other, or if the benefits of the two techniques are additive.
Comparison:
This study aims to assess if one technique confers more benefit than the other and if the benefits are additive. This is important as many centres do not use thoracic epidural analgesia for cardiac surgery and not all clinicians currently use volatile anaesthetics for cardiac surgery.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Martin F McCormick, MB ChB
- Phone Number: 44 141 951 5600
- Email: Martin.McCormick@gjnh.scot.nhs.uk
Study Contact Backup
- Name: Stefan Schraag, MD PhD
- Phone Number: 44 141 951 5609
- Email: Stefan.Schraag@gjnh.scot.nhs.uk
Study Locations
-
-
-
Glasgow, United Kingdom, G81 4HX
- Golden Jubilee National Hospital
-
Contact:
- Martin F McCormick, MB ChB
- Phone Number: 44 141 951 5600
- Email: Martin.McCormick@gjnh.scot.nhs.uk
-
Contact:
- Stefan Schraag, MD PhD
- Phone Number: 44 141 951 5609
- Email: Stefan.Schraag@gjnh.scot.nhs.uk
-
Principal Investigator:
- Martin F McCormick, MB ChB
-
Sub-Investigator:
- Jorg Prinzlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients presenting for elective CABG operations, with >40 % left ventricular ejection fraction, aged 40-80.
Exclusion Criteria:
- Patients at risk of epidural haematomas (i.e. platelets <100, coagulopathies, on anticoagulant therapies, INR>1.4) or unsuited to HTEA (patient refusal, spinal deformities).
Patients on drugs shown to manipulate the preconditioning phenomenon will also be excluded. This includes those on diazoxide, nicorandil, oral sulfonylureas and theophyllines.
Patients with preoperative ECG morphologies likely to make interpretation difficult or impossible including: left bundle branch block, cardiac pacemaker dependence.
Haemodynamically compromised patients requiring inotropic or balloon pump support preoperatively.
Significant valvular disease. Preoperative elevated levels of troponin I or CKMB. Unstable angina or angina in 24 hours preop
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Plasma concentration of NT-proBNP as a biochemical marker of ventricular dysfunction
|
Secondary Outcome Measures
Outcome Measure |
---|
Changes in plasma measurements of cardiac troponin I and CK-MB from baseline over the first two poatoperative days.
|
Cardiac morbidity/ mortality as defined by incidence of death, inotrope requirements, arrhythmias, left ventricular dysfunction, pulmonary oedema or myocardial infarction
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Stefan Schraag, MD PhD, Golden Jubilee National Hospital
- Principal Investigator: Martin F McCormick, MB ChB, Golden Jubilee National Hospital
Publications and helpful links
General Publications
- Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot PG, Schmid ER, Turina MI, von Segesser LK, Pasch T, Spahn DR, Zaugg M. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology. 2003 Jun;98(6):1315-27. doi: 10.1097/00000542-200306000-00004.
- Berendes E, Schmidt C, Van Aken H, Hartlage MG, Wirtz S, Reinecke H, Rothenburger M, Scheld HH, Schluter B, Brodner G, Walter M. Reversible cardiac sympathectomy by high thoracic epidural anesthesia improves regional left ventricular function in patients undergoing coronary artery bypass grafting: a randomized trial. Arch Surg. 2003 Dec;138(12):1283-90; discussion 1291. doi: 10.1001/archsurg.138.12.1283.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- gjnh/mccormick/01
- EUDRACT no. 2005-004398-76
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Bypass Surgery
-
The Medicines CompanyCompletedCardiac Surgery | Coronary Artery Bypass SurgeryUnited States
-
Maria Cecilia HospitalRecruitingCoronary Artery Bypass SurgeryItaly
-
Ajou University School of MedicineNot yet recruitingCoronary Artery Bypass SurgeryKorea, Republic of
-
Universidade do Sul de Santa CatarinaICSCCompleted
-
Swiss Cardio Technologies AGCompletedValve Surgery | Coronary Artery Bypass SurgeryGermany, Austria
-
London Health Sciences CentreTerminated
-
Hasselt UniversityCompletedCoronary Artery Bypass SurgeryBelgium
-
Baskent UniversityUnknownCoronary Artery Bypass SurgeryTurkey
-
University Hospital Birmingham NHS Foundation TrustUnknownCoronary Artery Bypass SurgeryUnited Kingdom
-
Università Vita-Salute San RaffaeleCompletedCardiac Surgery | Coronary Artery Bypass Grafting | Aortocoronary BypassCroatia, Italy, China, Malaysia, Russian Federation, Portugal, Bahrain, Brazil, Bulgaria, Czechia, Egypt, Saudi Arabia, Serbia
Clinical Trials on Sevoflurane
-
Yeungnam University College of MedicineCompleted
-
University of RostockCompletedOther Specified Injuries of Vocal Cord, SequelaGermany
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceTerminated
-
Kocaeli Derince Education and Research HospitalCompleted
-
Pontificia Universidad Catolica de ChileUnknown
-
Universiti Sains MalaysiaCompletedGeneral Anaesthesia | PaediatricsMalaysia
-
University Hospital, Clermont-FerrandCompleted
-
University Hospital, GhentCompleted
-
Signe Sloth MadsenCompletedHealthy Volunteers | General Anaesthesia | NeuroplasticityDenmark